Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Retained Earnings (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Retained Earnings readings, the most recent being -$182.8 million for Q1 2026.

  • Quarterly Retained Earnings fell 3656300.0% to -$182.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$182.8 million through Mar 2026, down 3656300.0% year-over-year, with the annual reading at $50000.0 for FY2025, 100.04% up from the prior year.
  • Retained Earnings hit -$182.8 million in Q1 2026 for DiaMedica Therapeutics, down from $50000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $50000.0 in Q3 2025 and bottomed at -$182.8 million in Q1 2026.
  • Average Retained Earnings over 5 years is -$86.0 million, with a median of -$101.4 million recorded in 2023.
  • The largest annual shift saw Retained Earnings surged 100.04% in 2025 before it plummeted 3656300.0% in 2026.
  • DiaMedica Therapeutics' Retained Earnings stood at -$96.2 million in 2022, then fell by 20.15% to -$115.6 million in 2023, then dropped by 21.15% to -$140.0 million in 2024, then surged by 100.04% to $50000.0 in 2025, then plummeted by 365720.0% to -$182.8 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Retained Earnings are -$182.8 million (Q1 2026), $50000.0 (Q4 2025), and $50000.0 (Q3 2025).